How to Buy jublpharma Shares on Fincept?
You can buy Jubilant Pharmova Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Jubilant Pharmova Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Jublpharma, including updates on board meetings and corporate actions.
Jubilant Pharmova Limited - https://www.jubilantpharmova.com
Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.
Jubilant Pharmova Limited Share Price Today
916.00
OPEN
979.00
HIGH
916.00
LOW
957.20
CLOSE
346 K
VOLUME
17,005 Cr
Market Cap
263983
Average Volume
Healthcare
Sector
NSI
Exchange
Jubilant Pharmova Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: JUBLPHARMA Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Jubilant Pharmova Limited |
JUBLPHARMA |
INE700A01033 |
Dividend - Rs 5 Per Share |
02 Aug 2024 |
1 |
N/A |
Jubilant Pharmova Limited |
JUBLPHARMA |
INE700A01033 |
Dividend - Rs 5 Per Share |
10 Aug 2023 |
1 |
N/A |
Jubilant Pharmova Limited |
JUBLPHARMA |
INE700A01033 |
Dividend - Rs 5 Per Share |
11 Aug 2022 |
1 |
N/A |
Jubilant Pharmova Limited |
JUBLPHARMA |
INE700A01033 |
Dividend - Rs 5 Per Share |
05 Aug 2021 |
1 |
N/A |
Jubilant Pharmova Limited |
JUBLPHARMA |
INE700A01033 |
Demerger |
04 Feb 2021 |
1 |
N/A |
NSE: JUBLPHARMA Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
JUBLPHARMA |
24 Dec 2024, 18:51:58 |
Trading Window-XBRL |
N/A |
JUBLPHARMA |
24 Dec 2024, 18:50:50 |
Trading Window |
N/A |
JUBLPHARMA |
10 Dec 2024, 18:49:23 |
Credit Rating |
N/A |
JUBLPHARMA |
05 Nov 2024, 11:40:58 |
Updates |
N/A |
JUBLPHARMA |
27 Oct 2024, 00:08:52 |
Copy of Newspaper Publication |
N/A |
NSE: JUBLPHARMA Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Jubilant Pharmova Limited |
JUBLPHARMA |
19 Oct 2024, 11:37:00 |
19 Oct 2024, 11:37:00 |
|
Jubilant Pharmova Limited |
JUBLPHARMA |
11 Jul 2024, 10:47:00 |
11 Jul 2024, 10:47:00 |
|
Jubilant Pharmova Limited |
JUBLPHARMA |
19 Apr 2024, 18:49:00 |
19 Apr 2024, 19:15:00 |
|
Jubilant Pharmova Limited |
JUBLPHARMA |
19 Jan 2024, 17:45:00 |
19 Jan 2024, 18:15:00 |
|
Jubilant Pharmova Limited |
JUBLPHARMA |
18 Oct 2023, 19:45:00 |
18 Oct 2023, 20:15:00 |
NSE: JUBLPHARMA Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Non-Executive Director |
09 Nov 1952 |
21 Jun 1978 |
00010484 |
Shyam Sunder Bhartia |
Active |
Non-Executive Director |
12 Dec 1956 |
01 Nov 1983 |
00010499 |
Hari Shanker Bhartia |
Active |
Independent Director |
09 May 1950 |
23 May 2017 |
00309302 |
Sushil Kumar Roongta |
Active |
Independent Director |
21 Apr 1955 |
23 May 2017 |
00101328 |
Vivek Mehra |
Active |
Independent Director |
19 Nov 1951 |
22 Oct 2018 |
00204434 |
Arun Seth |
Active |
NSE: JUBLPHARMA Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 25-Oct-2024 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2024 . |
JUBLPHARMA |
N/A |
INE700A01033 |
Jubilant Pharmova Limited |
17 Oct 2024, 18:26:54 |
Financial Results |
JUBLPHARMA |
N/A |
INE700A01033 |
Jubilant Pharmova Limited |
10 Jul 2024, 18:08:43 |
JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend. |
JUBLPHARMA |
N/A |
INE700A01033 |
Jubilant Pharmova Limited |
22 May 2024, 12:03:12 |
Financial Results |
JUBLPHARMA |
N/A |
INE700A01033 |
Jubilant Pharmova Limited |
23 Jan 2024, 18:29:02 |
Financial Results |
JUBLPHARMA |
N/A |
INE700A01033 |
Jubilant Pharmova Limited |
19 Oct 2023, 15:55:09 |
NSE: JUBLPHARMA Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
JUBLPHARMA |
- |
INE700A01033 |
Jubilant Pharmova Limited |
17 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Financial Results |
JUBLPHARMA |
- |
INE700A01033 |
Jubilant Pharmova Limited |
10 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results/Dividend |
JUBLPHARMA |
- |
INE700A01033 |
Jubilant Pharmova Limited |
22 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 and dividend |
Financial Results |
JUBLPHARMA |
- |
INE700A01033 |
Jubilant Pharmova Limited |
23 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 |
Financial Results |
JUBLPHARMA |
- |
INE700A01033 |
Jubilant Pharmova Limited |
19 Oct 2023, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2023 |
NSE: JUBLPHARMA Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Tradeand Other Payables Non Current | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Available For Sale Securities | Financial Assets Designatedas Fair Value Through Profitor Loss | Long Term Equity Investment | Investmentsin Associatesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Assets Held For Sale Current | Current Deferred Taxes Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 884,410.00 | 158,396,729.00 | 159,281,139.00 | 17,481,000,000.00 | 30,804,000,000.00 | 23,872,000,000.00 | 87,655,000,000.00 | 15,550,000,000.00 | 23,872,000,000.00 | 2,554,000,000.00 | 59,405,000,000.00 | 84,824,000,000.00 | 59,270,000,000.00 | -135,000,000.00 | 59,405,000,000.00 | 59,247,000,000.00 | 0.00 | 0.00 | 158,000,000.00 | 158,000,000.00 | 59,974,000,000.00 | 40,506,000,000.00 | 8,520,000,000.00 | 0.00 | 0.00 | 2,187,000,000.00 | 27,450,000,000.00 | 2,031,000,000.00 | 25,419,000,000.00 | 1,022,000,000.00 | 19,468,000,000.00 | 1,692,000,000.00 | 3,354,000,000.00 | 523,000,000.00 | 2,831,000,000.00 | 654,000,000.00 | 8,335,000,000.00 | 0.00 | 0.00 | 77,000,000.00 | 8,258,000,000.00 | 119,244,000,000.00 | 84,226,000,000.00 | 2,628,000,000.00 | 0.00 | 2,461,000,000.00 | 552,000,000.00 | 552,000,000.00 | 0.00 | 79,000,000.00 | 79,000,000.00 | 35,533,000,000.00 | 10,733,000,000.00 | 24,800,000,000.00 | 42,659,000,000.00 | 0.00 | 42,659,000,000.00 | 18,574,000,000.00 | 24,085,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35,018,000,000.00 | 2,190,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11,615,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12,000,000.00 | 366,000,000.00 | 7,950,000,000.00 | 0.00 | 0.00 | 12,885,000,000.00 | 2,116,000,000.00 | 10,769,000,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 930,402.00 | 158,350,737.00 | 159,281,139.00 | 24,602,000,000.00 | 36,640,000,000.00 | 19,267,000,000.00 | 88,480,000,000.00 | 19,871,000,000.00 | 19,267,000,000.00 | 2,499,000,000.00 | 54,339,000,000.00 | 86,010,000,000.00 | 54,211,000,000.00 | -128,000,000.00 | 54,339,000,000.00 | 145,000,000.00 | 45,397,000,000.00 | 398,000,000.00 | 158,000,000.00 | 158,000,000.00 | 61,274,000,000.00 | 42,384,000,000.00 | 5,438,000,000.00 | 188,000,000.00 | 5,438,000,000.00 | 2,108,000,000.00 | 33,649,000,000.00 | 1,978,000,000.00 | 31,671,000,000.00 | 1,001,000,000.00 | 18,890,000,000.00 | 1,632,000,000.00 | 2,991,000,000.00 | 521,000,000.00 | 2,470,000,000.00 | 664,000,000.00 | 14,237,000,000.00 | 5,279,000,000.00 | 25,000,000.00 | 370,000,000.00 | 8,563,000,000.00 | 115,485,000,000.00 | 76,724,000,000.00 | 8,000,000.00 | 1,776,000,000.00 | 2,327,000,000.00 | 344,000,000.00 | 322,000,000.00 | 22,000,000.00 | 78,000,000.00 | 78,000,000.00 | 35,072,000,000.00 | 10,433,000,000.00 | 24,639,000,000.00 | 36,871,000,000.00 | -19,972,000,000.00 | 56,843,000,000.00 | 12,523,000,000.00 | 24,348,000,000.00 | 32,898,000,000.00 | 10,543,000,000.00 | 879,000,000.00 | 0.00 | 38,761,000,000.00 | 10,000,000.00 | 2,439,000,000.00 | 0.00 | 29,000,000.00 | 1,085,000,000.00 | 12,896,000,000.00 | 0.00 | 3,267,000,000.00 | 3,500,000,000.00 | 6,129,000,000.00 | 3,350,000,000.00 | 167,000,000.00 | 9,159,000,000.00 | -668,000,000.00 | 9,827,000,000.00 | 9,626,000,000.00 | 87,000,000.00 | 9,539,000,000.00 | 519,000,000.00 | 9,020,000,000.00 |
| 2024-03-31T00:00:00 | annual | 930,402.00 | 158,350,737.00 | 159,281,139.00 | 24,602,000,000.00 | 36,640,000,000.00 | 19,267,000,000.00 | 88,480,000,000.00 | 19,871,000,000.00 | 19,267,000,000.00 | 2,499,000,000.00 | 54,339,000,000.00 | 86,010,000,000.00 | 54,211,000,000.00 | -128,000,000.00 | 54,339,000,000.00 | 145,000,000.00 | 45,397,000,000.00 | 398,000,000.00 | 158,000,000.00 | 158,000,000.00 | 61,274,000,000.00 | 42,384,000,000.00 | 5,438,000,000.00 | 188,000,000.00 | 5,438,000,000.00 | 2,108,000,000.00 | 33,649,000,000.00 | 1,978,000,000.00 | 31,671,000,000.00 | 1,001,000,000.00 | 18,890,000,000.00 | 1,632,000,000.00 | 2,991,000,000.00 | 521,000,000.00 | 2,470,000,000.00 | 664,000,000.00 | 14,237,000,000.00 | 5,279,000,000.00 | 25,000,000.00 | 370,000,000.00 | 8,563,000,000.00 | 115,485,000,000.00 | 76,724,000,000.00 | 8,000,000.00 | 1,776,000,000.00 | 2,327,000,000.00 | 344,000,000.00 | 322,000,000.00 | 22,000,000.00 | 78,000,000.00 | 78,000,000.00 | 35,072,000,000.00 | 10,433,000,000.00 | 24,639,000,000.00 | 36,871,000,000.00 | -19,972,000,000.00 | 56,843,000,000.00 | 12,523,000,000.00 | 24,348,000,000.00 | 32,898,000,000.00 | 10,543,000,000.00 | 879,000,000.00 | 0.00 | 38,761,000,000.00 | 10,000,000.00 | 2,439,000,000.00 | 0.00 | 29,000,000.00 | 1,085,000,000.00 | 12,896,000,000.00 | 0.00 | 3,267,000,000.00 | 3,500,000,000.00 | 6,129,000,000.00 | 3,350,000,000.00 | 167,000,000.00 | 9,159,000,000.00 | -668,000,000.00 | 9,827,000,000.00 | 9,626,000,000.00 | 87,000,000.00 | 9,539,000,000.00 | 519,000,000.00 | 9,020,000,000.00 |
| 2023-09-30T00:00:00 | quarterly | 931,894.00 | 158,349,245.00 | 159,281,139.00 | 24,461,000,000.00 | 36,679,000,000.00 | 19,449,000,000.00 | 88,299,000,000.00 | 18,162,000,000.00 | 19,449,000,000.00 | 2,481,000,000.00 | 54,101,000,000.00 | 85,797,000,000.00 | 54,014,000,000.00 | -87,000,000.00 | 54,101,000,000.00 | 53,943,000,000.00 | 0.00 | 0.00 | 158,000,000.00 | 158,000,000.00 | 59,982,000,000.00 | 42,080,000,000.00 | 4,018,000,000.00 | 0.00 | 0.00 | 3,214,000,000.00 | 33,669,000,000.00 | 1,973,000,000.00 | 31,696,000,000.00 | 933,000,000.00 | 17,902,000,000.00 | 1,167,000,000.00 | 3,010,000,000.00 | 508,000,000.00 | 2,502,000,000.00 | 734,000,000.00 | 9,349,000,000.00 | 0.00 | 0.00 | 111,000,000.00 | 9,238,000,000.00 | 113,996,000,000.00 | 77,932,000,000.00 | 1,583,000,000.00 | 0.00 | 2,339,000,000.00 | 534,000,000.00 | 534,000,000.00 | 0.00 | 2,335,000,000.00 | 2,335,000,000.00 | 34,652,000,000.00 | 10,137,000,000.00 | 24,515,000,000.00 | 36,183,000,000.00 | 0.00 | 36,183,000,000.00 | 10,946,000,000.00 | 25,237,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36,064,000,000.00 | 2,531,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13,280,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,000,000.00 | 235,000,000.00 | 9,036,000,000.00 | 0.00 | 0.00 | 10,972,000,000.00 | 1,235,000,000.00 | 9,737,000,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 209,457.00 | 159,071,682.00 | 159,281,139.00 | 23,993,000,000.00 | 36,768,000,000.00 | 20,197,000,000.00 | 88,094,000,000.00 | 19,900,000,000.00 | 20,197,000,000.00 | 2,667,000,000.00 | 53,993,000,000.00 | 85,097,000,000.00 | 53,918,000,000.00 | -75,000,000.00 | 53,993,000,000.00 | 62,000,000.00 | 45,368,000,000.00 | 398,000,000.00 | 159,000,000.00 | 159,000,000.00 | 57,649,000,000.00 | 39,925,000,000.00 | 2,685,100,000.00 | 19,000,000.00 | 2,685,000,000.00 | 3,062,000,000.00 | 33,237,000,000.00 | 2,133,000,000.00 | 31,104,000,000.00 | 922,000,000.00 | 17,724,000,000.00 | 1,217,800,000.00 | 3,531,000,000.00 | 534,000,000.00 | 2,997,000,000.00 | 783,000,000.00 | 12,691,000,000.00 | 3,823,000,000.00 | 31,000,000.00 | 624,000,000.00 | 8,213,000,000.00 | 111,567,000,000.00 | 73,943,000,000.00 | 9,000,000.00 | 1,133,000,000.00 | 2,275,000,000.00 | 328,000,000.00 | 308,000,000.00 | 20,000,000.00 | 2,236,000,000.00 | 2,236,000,000.00 | 33,796,000,000.00 | 9,510,000,000.00 | 24,286,000,000.00 | 33,652,000,000.00 | -15,176,000,000.00 | 48,828,000,000.00 | 7,733,000,000.00 | 25,918,700,000.00 | 29,425,000,000.00 | 10,807,000,000.00 | 863,000,000.00 | 0.00 | 37,624,000,000.00 | 56,000,000.00 | 0.00 | 0.00 | 35,000,000.00 | 1,379,000,000.00 | 13,805,000,000.00 | 12,590,000.00 | 2,945,000,000.00 | 4,534,000,000.00 | 6,326,000,000.00 | 2,469,000,000.00 | 116,000,000.00 | 9,612,000,000.00 | -505,000,000.00 | 10,117,000,000.00 | 10,152,000,000.00 | 44,000,000.00 | 10,108,000,000.00 | 180,000,000.00 | 9,928,000,000.00 |
| 2023-03-31T00:00:00 | annual | 209,457.00 | 159,071,682.00 | 159,281,139.00 | 23,993,000,000.00 | 36,768,000,000.00 | 20,197,000,000.00 | 88,094,000,000.00 | 19,900,000,000.00 | 20,197,000,000.00 | 2,667,000,000.00 | 53,993,000,000.00 | 85,097,000,000.00 | 53,918,000,000.00 | -75,000,000.00 | 53,993,000,000.00 | 62,000,000.00 | 45,368,000,000.00 | 398,000,000.00 | 159,000,000.00 | 159,000,000.00 | 57,649,000,000.00 | 39,925,000,000.00 | 2,685,100,000.00 | 19,000,000.00 | 2,685,000,000.00 | 3,062,000,000.00 | 33,237,000,000.00 | 2,133,000,000.00 | 31,104,000,000.00 | 922,000,000.00 | 17,724,000,000.00 | 1,217,800,000.00 | 3,531,000,000.00 | 534,000,000.00 | 2,997,000,000.00 | 783,000,000.00 | 12,691,000,000.00 | 3,823,000,000.00 | 31,000,000.00 | 624,000,000.00 | 8,213,000,000.00 | 111,567,000,000.00 | 73,943,000,000.00 | 9,000,000.00 | 1,133,000,000.00 | 2,275,000,000.00 | 328,000,000.00 | 308,000,000.00 | 20,000,000.00 | 2,236,000,000.00 | 2,236,000,000.00 | 33,796,000,000.00 | 9,510,000,000.00 | 24,286,000,000.00 | 33,652,000,000.00 | -15,176,000,000.00 | 48,828,000,000.00 | 7,733,000,000.00 | 25,918,700,000.00 | 29,425,000,000.00 | 10,807,000,000.00 | 863,000,000.00 | 0.00 | 37,624,000,000.00 | 56,000,000.00 | 0.00 | 0.00 | 35,000,000.00 | 1,379,000,000.00 | 13,805,000,000.00 | 12,590,000.00 | 2,945,000,000.00 | 4,534,000,000.00 | 6,326,000,000.00 | 2,469,000,000.00 | 116,000,000.00 | 9,612,000,000.00 | -505,000,000.00 | 10,117,000,000.00 | 10,152,000,000.00 | 44,000,000.00 | 10,108,000,000.00 | 180,000,000.00 | 9,928,000,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 159,281,139.00 | 159,281,139.00 | 19,473,530,000.00 | 31,920,020,000.00 | 21,494,860,000.00 | 82,461,790,000.00 | 19,175,910,000.00 | 21,494,860,000.00 | 2,643,860,000.00 | 53,185,630,000.00 | 77,828,050,000.00 | 53,164,000,000.00 | -21,630,000.00 | 53,185,630,000.00 | 36,630,000.00 | 46,850,170,000.00 | 398,360,000.00 | 159,190,000.00 | 159,190,000.00 | 46,744,670,000.00 | 30,828,660,000.00 | 73,000,000.00 | 5,040,000.00 | 72,960,000.00 | 3,029,650,000.00 | 26,764,350,000.00 | 2,121,930,000.00 | 24,642,420,000.00 | 956,660,000.00 | 15,916,010,000.00 | 1,518,600,000.00 | 5,155,670,000.00 | 521,930,000.00 | 4,633,740,000.00 | 868,390,000.00 | 8,979,440,000.00 | 2,921,420,000.00 | 35,560,000.00 | 345,060,000.00 | 5,677,400,000.00 | 99,908,670,000.00 | 64,816,750,000.00 | 9,460,000.00 | 1,056,680,000.00 | 1,612,710,000.00 | 434,930,000.00 | 369,270,000.00 | 65,660,000.00 | 1,951,070,000.00 | 1,951,070,000.00 | 31,690,770,000.00 | 9,263,230,000.00 | 22,427,540,000.00 | 27,910,990,000.00 | -12,400,970,000.00 | 40,311,960,000.00 | 2,918,260,000.00 | 24,992,800,000.00 | 26,300,470,000.00 | 10,218,100,000.00 | 875,130,000.00 | 0.00 | 35,091,920,000.00 | 32,940,000.00 | 0.00 | 0.00 | 39,740,000.00 | 1,188,510,000.00 | 12,548,690,000.00 | 13,380,000.00 | 3,146,060,000.00 | 3,792,580,000.00 | 5,596,670,000.00 | 2,144,100,000.00 | 1,840,000.00 | 9,279,940,000.00 | -258,790,000.00 | 9,538,730,000.00 | 9,856,160,000.00 | 53,530,000.00 | 9,802,630,000.00 | 290,760,000.00 | 9,511,870,000.00 |
| 2021-03-31T00:00:00 | annual | 107,140.00 | 159,173,999.00 | 159,281,139.00 | 20,860,380,000.00 | 28,295,630,000.00 | 18,109,380,000.00 | 73,254,590,000.00 | 19,036,680,000.00 | 18,109,380,000.00 | 2,455,900,000.00 | 47,414,860,000.00 | 73,054,580,000.00 | 47,415,170,000.00 | 310,000.00 | 47,414,860,000.00 | 8,160,000.00 | 43,177,110,000.00 | 398,360,000.00 | 159,190,000.00 | 159,190,000.00 | 41,765,930,000.00 | 31,277,600,000.00 | 270,200,000.00 | 194,500,000.00 | 75,710,000.00 | 2,473,020,000.00 | 27,594,280,000.00 | 1,954,560,000.00 | 25,639,720,000.00 | 940,090,000.00 | 10,488,330,000.00 | 1,009,500,000.00 | 701,350,000.00 | 501,340,000.00 | 200,010,000.00 | 898,060,000.00 | 8,341,880,000.00 | 2,628,710,000.00 | 40,220,000.00 | 468,110,000.00 | 5,204,840,000.00 | 89,181,100,000.00 | 59,656,090,000.00 | 520,000.00 | 539,700,000.00 | 1,547,120,000.00 | 428,200,000.00 | 336,670,000.00 | 91,530,000.00 | 1,981,400,000.00 | 1,981,400,000.00 | 29,305,480,000.00 | 8,005,860,000.00 | 21,299,620,000.00 | 25,751,930,000.00 | -9,928,300,000.00 | 35,680,230,000.00 | 2,777,800,000.00 | 2,770,000.00 | 22,095,390,000.00 | 9,937,620,000.00 | 869,420,000.00 | 0.00 | 29,525,010,000.00 | 3,220,000.00 | 0.00 | 0.00 | 102,190,000.00 | 977,880,000.00 | 11,293,810,000.00 | 11,470,000.00 | 2,755,390,000.00 | 3,472,200,000.00 | 5,054,750,000.00 | 1,858,690,000.00 | 236,110,000.00 | 8,199,040,000.00 | -219,810,000.00 | 8,418,850,000.00 | 6,854,070,000.00 | 1,874,720,000.00 | 4,979,350,000.00 | 221,210,000.00 | 4,758,140,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 101,900,000.00 | 3,350,000.00 | 0.00 | 0.00 | 0.00 | 689,430,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: JUBLPHARMA Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repurchase Of Capital Stock | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Payments | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Stock Based Compensation | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 736,000,000.00 | -274,000,000.00 | -759,000,000.00 | 1,172,000,000.00 | 0.00 | -8,977,000,000.00 | 9,564,000,000.00 | 0.00 | 10,139,000,000.00 | 116,000,000.00 | -691,000,000.00 | -4,325,000,000.00 | -2,437,000,000.00 | -798,000,000.00 | -798,000,000.00 | -274,000,000.00 | -274,000,000.00 | 0.00 | -204,000,000.00 | -617,000,000.00 | 0.00 | 413,000,000.00 | -759,000,000.00 | 1,172,000,000.00 | -6,079,000,000.00 | 2,299,000,000.00 | 257,000,000.00 | 268,000,000.00 | -23,000,000.00 | 57,000,000.00 | -80,000,000.00 | 0.00 | 0.00 | -8,880,000,000.00 | 97,000,000.00 | -8,977,000,000.00 | 0.00 | 9,713,000,000.00 | -2,077,000,000.00 | 2,531,000,000.00 | 329,000,000.00 | 232,000,000.00 | 908,000,000.00 | 1,062,000,000.00 | 4,151,000,000.00 | 85,000,000.00 | 3,819,000,000.00 | 521,000,000.00 | 3,298,000,000.00 | -2,000,000.00 | 14,000,000.00 | -2,000,000.00 | 1,705,000,000.00 |
| 2023-03-31T00:00:00 | annual | -1,538,000,000.00 | -40,000,000.00 | -27,730,000,000.00 | 28,104,000,000.00 | 0.00 | -8,145,000,000.00 | 10,139,000,000.00 | 0.00 | 9,838,000,000.00 | 705,000,000.00 | -404,000,000.00 | -1,567,000,000.00 | -2,342,000,000.00 | -801,000,000.00 | -801,000,000.00 | -40,000,000.00 | -40,000,000.00 | 0.00 | 2,317,000,000.00 | 1,943,000,000.00 | 0.00 | 374,000,000.00 | -27,730,000,000.00 | 28,104,000,000.00 | -5,444,000,000.00 | 2,445,000,000.00 | 100,000,000.00 | 88,000,000.00 | -118,000,000.00 | 9,000,000.00 | -127,000,000.00 | 0.00 | 0.00 | -7,959,000,000.00 | 186,000,000.00 | -8,145,000,000.00 | 0.00 | 6,607,000,000.00 | -2,043,000,000.00 | 543,000,000.00 | -2,742,000,000.00 | 2,105,000,000.00 | -647,000,000.00 | 1,827,000,000.00 | 2,352,000,000.00 | 37,000,000.00 | 5,540,000,000.00 | 2,379,000,000.00 | 3,161,000,000.00 | 50,000,000.00 | -54,000,000.00 | 27,000,000.00 | 278,000,000.00 |
| 2022-03-31T00:00:00 | annual | 2,375,520,000.00 | 0.00 | -49,960,000.00 | 2,031,770,000.00 | 0.00 | -5,999,910,000.00 | 9,838,190,000.00 | 0.00 | 5,019,570,000.00 | 572,880,000.00 | 4,245,740,000.00 | -325,990,000.00 | -1,349,370,000.00 | -800,530,000.00 | -800,530,000.00 | 0.00 | 0.00 | 0.00 | 2,421,800,000.00 | 439,990,000.00 | 0.00 | 1,981,810,000.00 | -49,960,000.00 | 2,031,770,000.00 | -3,803,700,000.00 | 1,702,900,000.00 | 40,210,000.00 | 0.00 | 2,120,820,000.00 | 2,144,010,000.00 | -23,190,000.00 | 0.00 | 0.00 | -5,964,730,000.00 | 35,180,000.00 | -5,999,910,000.00 | 0.00 | 8,375,430,000.00 | -1,940,910,000.00 | -1,782,870,000.00 | -428,720,000.00 | 1,580,000.00 | -956,470,000.00 | -399,260,000.00 | 1,430,350,000.00 | 11,240,000.00 | 3,817,040,000.00 | 895,470,000.00 | 2,921,570,000.00 | -1,470,000.00 | 404,050,000.00 | 33,700,000.00 | 6,304,470,000.00 |
| 2021-03-31T00:00:00 | annual | 12,567,710,000.00 | 0.00 | -19,499,660,000.00 | 12,301,220,000.00 | -100,610,000.00 | -5,274,940,000.00 | 5,019,570,000.00 | -769,810,000.00 | 12,308,140,000.00 | 122,590,000.00 | -6,641,350,000.00 | -17,093,860,000.00 | -2,922,350,000.00 | -14,750,000.00 | -14,750,000.00 | -100,610,000.00 | 0.00 | -100,610,000.00 | -13,497,390,000.00 | -6,298,950,000.00 | 0.00 | -7,198,440,000.00 | -19,499,660,000.00 | 12,301,220,000.00 | -7,390,140,000.00 | -264,080,000.00 | 41,190,000.00 | 0.00 | -2,288,340,000.00 | 0.00 | -2,288,340,000.00 | 0.00 | 0.00 | -5,142,990,000.00 | 131,950,000.00 | -5,274,940,000.00 | 0.00 | 17,842,650,000.00 | -3,941,200,000.00 | 2,499,000,000.00 | 0.00 | 2,282,590,000.00 | 1,343,210,000.00 | -1,126,800,000.00 | 2,546,270,000.00 | 0.00 | 4,516,480,000.00 | 884,970,000.00 | 3,631,510,000.00 | -29,890,000.00 | 174,310,000.00 | 70,100,000.00 | 12,120,100,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 2,620,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,620,000.00 | 0.00 | 0.00 | 1,501,760,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5,741,530,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: JUBLPHARMA Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Discontinuous Operations | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Impairment Of Capital Assets | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -50.61 | 0.00 | 977.50 | -168.70 | -168.70 | 77.10 | 381.90 | 2,422.10 | 808.80 | 426.90 | -246.20 | 256.40 | 26.10 | 195.19 | 77.10 | 6,121.70 | 4.90 | 15.89 | 15.85 | 0.00 | 0.00 | 77.10 | 77.10 | 0.00 | 77.10 | 4.40 | 72.70 | 0.00 | 72.70 | 97.80 | 170.50 | 15.40 | -168.90 | 168.90 | 0.00 | 0.00 | -246.20 | 15.90 | 256.40 | 26.10 | 523.10 | 3,699.60 | 703.80 | 381.90 | 52.10 | 329.80 | 440.60 | 214.30 | 226.30 | 4.90 | 4,222.70 | 2,422.10 | 6,644.80 | 6,644.80 |
| 2023-03-31T00:00:00 | annual | -19.35 | 0.00 | 814.90 | -64.50 | -64.50 | -61.00 | 554.00 | 2,222.80 | 750.40 | 196.40 | -178.40 | 168.60 | 9.80 | -15.85 | -61.00 | 5,989.40 | 7.80 | 15.91 | 15.91 | 0.00 | 0.00 | -61.00 | -61.00 | 0.00 | -61.00 | 3.90 | -64.90 | 0.00 | -64.90 | 92.70 | 27.80 | 11.30 | -59.50 | 59.50 | 0.00 | 0.00 | -178.40 | 19.60 | 168.60 | 9.80 | 229.90 | 3,766.60 | 680.00 | 554.00 | 237.90 | 316.10 | 384.70 | 161.60 | 223.10 | 7.80 | 3,996.50 | 2,222.80 | 6,219.30 | 6,219.30 |
| 2022-03-31T00:00:00 | annual | -1.11 | 0.00 | 1,153.62 | -3.22 | -3.22 | 413.94 | 381.70 | 1,786.99 | 1,150.39 | 768.69 | -143.04 | 138.24 | 2.45 | 416.05 | 413.94 | 5,234.71 | 4.50 | 15.92 | 15.92 | 0.00 | 0.00 | 413.94 | 413.94 | 0.00 | 413.94 | 0.92 | 413.02 | 0.00 | 413.02 | 217.43 | 630.45 | 8.69 | -3.37 | 3.37 | 0.00 | 0.00 | -143.04 | 7.25 | 138.24 | 2.45 | 824.45 | 3,447.73 | 609.71 | 381.70 | 89.55 | 292.16 | 455.51 | 209.71 | 245.80 | 4.50 | 4,272.18 | 1,786.99 | 6,059.17 | 6,059.17 |
| 2021-03-31T00:00:00 | annual | -8.56 | 0.00 | 1,521.18 | -25.10 | -25.10 | 574.12 | 451.65 | 1,753.45 | 1,496.08 | 1,044.43 | -176.00 | 173.36 | 8.10 | 590.65 | 835.87 | 4,845.20 | 4.91 | 15.93 | 15.93 | 0.00 | 0.00 | 835.87 | 835.87 | 0.00 | 835.87 | 0.26 | 835.61 | 261.75 | 573.86 | 297.22 | 871.08 | 6.72 | -27.92 | 27.92 | 0.00 | 0.00 | -176.00 | 10.74 | 173.36 | 8.10 | 1,118.67 | 3,091.75 | 525.13 | 348.95 | 88.50 | 260.45 | 409.41 | 177.15 | 232.26 | 4.91 | 4,210.42 | 1,753.45 | 5,963.88 | 5,963.88 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 220.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 11.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
37.37
P/E
28.688787
P/B
2.8674822
Dividend Yield
0.47%
Market Cap
17,004.90 Cr.
Face Value
373.882
Book Value
373.882
ROE
8.57%
EBITDA Growth
922.80 Cr.
Debt/Equity
51.972
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of jublpharma?
The market capitalization of Jubilant Pharmova Limited is ₹17,005 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Jubilant Pharmova Limited?
The PE and PB ratios of Jubilant Pharmova Limited are Not Available and 2.8674822 respectively as of 05 Feb 2025.
What is the 52 Week High of Jubilant Pharmova Limited?
The 52-week high of Jubilant Pharmova Limited is ₹1309.9 as of 05 Feb 2025.
What is the 52 Week Low of Jubilant Pharmova Limited?
The 52-week low of Jubilant Pharmova Limited is ₹526.05 as of 05 Feb 2025.
What are the earnings per share (EPS) for Jubilant Pharmova Limited?
The Earnings Per Share (EPS) of Jubilant Pharmova Limited is ₹37.37 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Jubilant Pharmova Limited?
The Return on Equity (ROE) of Jubilant Pharmova Limited is 8.57% as per the most recent financial year data. Explore more on Fincept.